Global purchasing managers have been seeking to de-risk procurement from China for many years. They have been working on this, but post-COVID and due to recent geopolitical challenges, this trend has accelerated.
Indian pharma stocks are rebounding, driven by domestic investors after a period of Foreign Institutional Investor (FII) selling pressure. Uncertainty surrounding potential US tariffs, fueled
Savy Infra’s shares debuted on the NSE SME platform with a 13.75% premium, listing at Rs 136.5 against an issue price of Rs 120, driven
Advertiser Disclosure
Great-investor.com helps users across the globe to find out The latest news, Guides, and Info about finance and investments. Furthermore, our content and research teams do not participate in any advertising planning nor are they permitted access to advertising campaign data.
Disclaimer
It is our organization’s primary mission to provide reviews, commentary, and analysis that are unbiased and objective. While great-investor.com has some data verified by industry participants, it can vary from time to time. Operating as an online business, this site may be compensated through third party advertisers. Our receipt of such compensation shall not be construed as an endorsement or recommendation by great-investor.com, nor shall it bias our reviews, analysis, and opinions. Please see our General Disclaimers for more information
Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003